| Active substance |
Apremilast |
| Also known as |
CC-10004 |
| Blood pressure |
No significant effects on blood pressure |
| Chemical name |
N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide |
| Dosage (medical) |
30 mg twice daily after initial titration |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces inflammation by inhibiting PDE4, an enzyme involved in the process of inflammatory response |
| Formula |
C22H24N2O7S |
| Half-life |
Approximately 6-9 hours |
| Hepatotoxicity |
Minimal to no hepatotoxicity reported |
| Lab Test |
Monitoring is not typically required for liver enzymes unless under specific medical advice |
| Main action |
Anti-inflammatory |
| Side effects |
Diarrhea, nausea, headache, upper respiratory tract infection, weight loss |
| Storage conditions |
Store at 20В°C to 25В°C (68В°F to 77В°F), excursions permitted between 15В°C to 30В°C (59В°F to 86В°F) |
| Strength |
30mg |
| Substance class |
Phosphodiesterase 4 (PDE4) inhibitor |
| Trade name |
Otezla |
| Use in sports |
Not typically used in sports, lacks performance-enhancing properties |
| Water Retention |
No significant effect |
| Manufacturer |
Glenmark Pharmaceuticals Ltd. |
| Packing |
10 tabs/blister |
